Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Biogen
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Age: 18 years and older
Diagnosis of B-cell CLL by International Workshop on CLL (IWCLL) response criteria
Relapsed CD23+ B-cell CLL
Rai Stage III or IV, or Rai Stage I or II if determined to have disease progression as evidenced by rapid doubling or peripheral lymphocyte count, progressive lymphadenopathy, progressive splenomegaly, or B symptoms
Prestudy WHO Performance Status less than or equal to 2
Signed, written Institutional Review Board (IRB)-approved informed consent
Men \& women of reproductive potential must agree to follow accepted birth control methods during treatment for 3 months after completion of treatment
Acceptable liver function: Bilirubin less than or equal to 2.0 mg/dL (26 µmol/L), AST (SGOT) \&/or ALT (SGPT) less than or equal to 2 times upper limit of normal
Acceptable hematologic status: Platelet count less than or equal to 50 x 10\^9/L, ANC less than or equal to 1 x 109/L
Acceptable renal function: Serum creatinine less than or equal to 1.5 times upper limit of normal
You may not be if
Subjects who did not respond to prior FCR therapy (relapsed within 6 months of the last dose).
Cancer radiotherapy, radioimmunotherapy, biological therapy, chemotherapy, or other investigational therapy within 4 weeks prior to Study Day 1
Previous exposure to lumiliximab or other anti-CD23 antibodies
Subjects who have had a prior allogenic bone marrow transplant (BMT) or autologous BMT or peripheral stem-cell transplant (PBSCT)
Known infection with HIV, hepatitis B, or hepatitis C
Uncontrolled diabetes mellitus
Uncontrolled hypertension
Transformation to aggressive B-cell malignancy (e.g., larger B-cell lymphoma, Richter's Syndrome, or prolymphocyte leukemia (PLL)
Subjects with secondary malignancy requiring active treatment (except hormonal therapy)
Subjects with medical conditions currently requiring long-term use (less than 1 month) of systemic corticosteroids
Serious nonmalignant disease or laboratory abnormality, which, in the opinion of the investigator \&/or sponsor, would compromise protocol objectives
Active uncontrolled bacteria, viral, or fungal infections
New York Heart Association Class III or IV cardiac disease, myocardial infarction within the past 6 months prior to Study Day 1, unstable arrhythmia, or evidence of ischemia on ECG within 14 days prior to Study Day 1
